Re: Enzalutamide effective in non-metastatic prostate cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Enzalutamide effective in non-metastatic prostate cancer

posted on Jun 29, 2018 10:51AM

Koo, yes you are mising the point. It's all about increasing the number of potential patients who could benefit from ZEN-3694.

Right now for non-metastatic, castration resistant prostate cancer, observation plus continuous androgen-deprivation therapy is considered to be the standard of care. Enzalutamide is currently approved for only metastatic castrate resistant prostate cancer. Enzalutamide resistance will eventually occur in both metastatic and non-metastatic castrate resistant prostate cancer. ZEN-3694 circumvents this enzalutamide resistance. Therefore, if the non-metastatic, castration resistant prostate cancer patient population is approved to start use of enzalutamide prior to the cancer becoming metastatic, then this increases the potential patient pool that will become enzalutamide resistant and potentially benefit from ZEN-3694.